Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sporanox generic launches

Executive Summary

Eon launches first generic of Janssen's antifungal Sporanox (itraconazole) Feb. 9. Eon, which holds 180-day marketing exclusivity on itraconazole 100 mg capsules, received ANDA approval in May but was barred from launching by a temporary restraining order in Janssen's patent infringement lawsuit (1"The Pink Sheet" June 7, 2004, In Brief). A federal judge ruled in July that Eon's ANDA does not infringe; the case is under appeal. Eon says it timed its launch for the start of the heavy prescribing season for itraconazole...

You may also be interested in...



Sporanox patent ruling

Trial court's ruling that Eon's generic Sporanox (itraconazole) does not infringe a Janssen patent affirmed by the Federal Circuit June 13. Eon launched its generic in February with 180 days of marketing exclusivity (1"The Pink Sheet" Feb. 14, 2005, In Brief)...

Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel